Hualan Biological Vaccine Inc Class A 301207
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 15.59
- Price/Sales
- 4.74
- Dividend Yield (Trailing)
- 3.32%
- Dividend Yield (Forward)
- 3.32%
- Total Yield
- 3.32%
Company Profile
Hualan Biological Vaccine Inc is engaged in Research, development, production and sales of human vaccines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 770
- Website
- http://www.hualanbacterin.com
Comparables
Valuation
Metric
|
301207
|
300122
|
300149
|
---|---|---|---|
Price/Earnings (Normalized) | 15.59 | 11.23 | — |
Price/Book Value | 1.84 | 2.11 | 2.17 |
Price/Sales | 4.74 | 1.43 | 2.76 |
Price/Cash Flow | 11.51 | 9.26 | 22.49 |
Price/Earnings
301207
300122
300149
Financial Strength
Metric
|
301207
|
300122
|
300149
|
---|---|---|---|
Quick Ratio | 2.85 | 1.37 | 1.46 |
Current Ratio | 3.42 | 2.07 | 1.71 |
Interest Coverage | 149.96 | 76.85 | −32.05 |
Quick Ratio
301207
300122
300149
Profitability
Metric
|
301207
|
300122
|
300149
|
---|---|---|---|
Return on Assets (Normalized) | 9.24% | 11.64% | −34.73% |
Return on Equity (Normalized) | 11.52% | 19.62% | −54.47% |
Return on Invested Capital (Normalized) | 10.82% | 17.67% | −38.80% |
Return on Assets
301207
300122
300149
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk AS ADR
NVO
| Gzjtjrwdx | Zwyrs | $531.4 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Hctyhpfpv | Zydkpr | $119.5 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Mrbwknlb | Hjcxqy | $114.9 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Wjyrgnrk | Ygllyq | $35.3 Bil | |||
argenx SE ADR
ARGX
| Spcjbwzmm | Jwhst | $32.0 Bil | |||
BioNTech SE ADR
BNTX
| Ngklyqg | Ntpt | $28.1 Bil | |||
Moderna Inc
MRNA
| Bbcwmyl | Cyntn | $25.3 Bil | |||
United Therapeutics Corp
UTHR
| Ncdtqjq | Gkbh | $16.0 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Mfvtklh | Lrydpfc | $13.4 Bil | |||
Incyte Corp
INCY
| Xdqhvvcmq | Bkyjsf | $12.7 Bil |